Evolution of meningococcal carriage in serogroups X and Y before introduction of MenAfriVac in the health district of Kaya, Burkina Faso

BMC Infectious Diseases

Juliette Tranchot³  Simon Tiendrebeogo⁵  Maxime Kienou¹  Kalifa Ouattara¹  Rasmata Ouédraogo⁴  Lassana Sangaré¹  Paul A Kristiansen⁶  Idrissa Sanou¹  Absatou Ky Ba² 

[1] Centre Hospitalier Universitaire Yalgado, Ouagadougou, Burkina Faso;Laboratoire National de Santé Publique, Ouagadougou, Burkina Faso;Universitaire Polytechnique de BoboDioulasso, Bobo-Dioulasso, Burkina Faso;Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso;Institut de Recherche en Science de la Santé, Ouagadougou, Burkina Faso;WHO Collaborating Center for Reference and Research on Meningococci, Norwegian Institute of Public Health, Oslo, Norway

关键词: Risk factor;    Carriage;    Serogroups X and Y;    Meningococcal meningitis;   

Others  :  1125422
DOI  :  10.1186/s12879-014-0546-8

 received in 2013-08-22, accepted in 2014-10-06,  发布年份 2014

【 摘 要 】

Background

The objective of this study was to evaluate the carriage of Neisseria meningitidis (Nm) serogroups X and Y in the health district of Kaya before the introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso.

Methods

A repeated cross-sectional meningococcal carriage study was conducted in 2009 in eight randomly selected villages in the health district of Kaya, Burkina Faso. In each of 4 sampling rounds at least 1,500 people were enrolled within a 1-month period.

Results

From a total of 6,686 throat swabs we identified 419 Nm isolates (6.27%). The dominating serogroups were Y (3.19%) and X (1.05%). Overall carriage was higher in the dry season compared with the rainy season (OR, 1.51; 95% CI, 1.06–2.16). Carriage prevalence of serogroups Y and X varied by round and was highest at the end of the dry season (4.92% and 1.22%, respectively). The only risk factor associated with NmX carriage was vaccination status in contrast to serogroup Y, which was associated with age groups 5–9 years and 10–14 years.

Conclusion

The presence of Nm serogroups X and Y, which could replace or be added to the serogroup A, is a warning sign. There is a need to strengthen surveillance and laboratory diagnosis of the various meningococcal serogroups circulating in Africa.

【 授权许可】

   
2014 Ba et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Jackou-B M, Michel R, Ollivier L, Meynard JB, Nicolas P, Boutin JP: Corrélation entre la pluviométrie et la méningite à méningocoque au Niger. Med Trop 2005, 65:329-333.
• [2]Miller JM, Mesaros N, Van DerWielen M, Baine Y: Conjugate meningococcal vaccines development: GSK biologicals experience. Adv Prev Med 2011, 10:4061-4078.
• [3]Qiuzhi C, Yih-Ling T, Stephens DS: Meningococcal disease: changes in epidemiology and prevention. Clin Epidemiol 2012, 4:237-245.
• [4]Alonso J-M, Bertherat É, Perea W, Borrow R, Chanteau S, Cohet C, Dodet B, Greenwood B, LaForce FM, Rouzic EM, Teyssou R, Ouédraogo TR, Sow I: Ceinture africaine de la méningite: de la génomique aux stratégies de surveillance de lutte et de prévention. Bull Soc Pathol Exot 2006, 99:404-408.
• [5]Djibo S, Nicolas P, Campagne G, Chippaux J-P: Portage rhino-pharyngé de méningocoque X dans une école primaire de Niamey (Niger). Med Trop 2004, 64:363-366.
• [6]Caugant DA, Maiden MCJ: Meningococcal carriage and disease—population biology and evolution. Vaccine 2009, 27:64-70.
• [7]Nathan N, Rose AMC, Legros D, Tiendrebeogo SRM, Bachy C, Bjørløw E, Firmenich P, Guerin PJ, Caugant DA: Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis 2007, 13:920-923.
• [8]Raghunathan PL, Jones JD, Tiendrebeogo SRM, Sanou I, Sangaré L, Kouanda S, Dabal M, Lingani C, Elie CM, Johnson S, Ari M, Martinez J, Chatt J, Sidibe K, Meyer LW, Konde MK, Djingarey MH, Popovic T, Plikaytis BD, Carlone GM, Rosenstein N, Sorriano-gabarro M: Predictors of Immunity after a Major Serogroup W135 Meningococcal Disease Epidemic, Burkina Faso, 2002. J Infect Dis 2006, 193:607-616.
• [9]Mueller JE, Sangaré L, Njanpop-Lafourcade B-M, Tarnagda Z, Traoré Y, Yaro S, Borrow R, Gessner BD, Nicolas P: Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003. Emerg Infect Dis 2007, 13:847-854.
• [10]Stephens DS, Greenwood B, Brandtzaeg P: Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369:2196-2210.
• [11]Manchanda V, Gupta S, Bhalla P: Meningococcal disease: history, epidemiology, manifestations, diagnosis, antimicrobial succeptibility and prevention. Indian J Med Microbiol 2006, 24:7-19.
• [12]Tan LKK, Carlone GM, Borrow R: Advances in the development of vaccines against Neisseria meningitides. New England J Med 2010, 362:1511-1520.
• [13]Kellermann S, McCombs K, Ray M, Baughman W, Reeves M, Popovic T, Rosenstein N, Farley M, Blake P, Stephens D: Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. J Infect Dis 2002, 186:40-48.
• [14]Lee HH: The Epidemiology of Meningococcal Disease in the United States. Clin Infect Dis 2010, 50:37-44.
• [15]Materu S, Cox HS, Isaakidis P, Baruani B, Ogaro T, Caugant DA: Serogroup X in meningococcal disease, Western Kenya. Emerg Infect Dis 2007, 13:944-945.
• [16]Kristiansen PA, Diomandé F, Wei SC, Ouédraogo R, Sangaré L, Sanou I, Kandolo D, Kaboré P, Clark TA, Ouédraogo A-S, Ba KA, Ouédraogo CD, Hassan-King M, Thomas JD, Hatcher C, Djingarey M, Messonnier N, Préziosi M-P, LaForce M, Caugant DA: Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup a conjugate vaccine. Clin Vacc Immunol 2011, 18:435-443.
• [17]Jordens ZJ, Williams JN, Jones GR, Christodoulides M, Heckels JE: Development of immunity to serogroup B Meningococci during carriage of Neisseria meningitidis in a cohort of university students. Infect Immun 2004, 72:6503-6510.
• [18]Plant L, Sundqvist J, Zughaier S, Lövkvist L, Stephens DS, Jonsson A-B: Lipooligosaccharide structure contributes to multiple steps in the virulence of Neisseria meningitidis. Infect Immun 2005, 74:1360-1367.
• [19]Kristiansen PA, Diomandé F, Ba Ki A, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Kandolo D, Aké F, Saga IM, Clark TA, Misegades L, Dolan J, Tiendrebeogo S, Hassan-King M, Djingarey M, Messonnier N, Préziosi MP, LaForce M, Caugant DA: Impact of the new serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013, 5:354-363.
• [20]Kristiansen PA, Ba KA, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Diomandé F, Kandolo D, Thomas JD, Clark TA, LaForce M, Caugant DA: Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine. BMC Infect Dis 2013, 13:363-372. BioMed Central Full Text
• [21]Craven DE, Frasch CE, Robbins JB, Feldman HA: Serogroup identification of Neisseria meningitidis: comparison of an antiserum agar method with bacterial slide agglutination. J Clin Microbiol 1978, 7:410-414.
• [22]Sidikou F, Djibo S, Taha MK, Alonso JM, Djibo A, Kairo KK, Chanteau S, Boisier P: Polymerase chain reaction assay and bacterial meningitis surveillance in remote areas, Niger. Emerg Infect Dis 2003, 9:1486-1488.
• [23]Boisier P, Nicolas P, Djibo S, Taha M-K, Jeanne I, Maınassara HB, Tenebray B, Kairo KK, Giorgini D, Chanteau S: Meningococcal Meningitis: Unprecedented Incidence of Serogroup X–Related Cases in 2006 in Niger. Clin Infect Dis 2007, 44:657-663.
• [24]Tsang RSW, Henderson AM, Cameron ML, Tyler SD, Tyson S, Law DKS, Stoltz J, Zollinger WD: Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol 2007, 45:1753-1758.
• [25]Burian V, Fofana Y, Sow O: Etude de Neisseria meningitidis isolés en République du Mali en 1970. Bull World Health Organ 1974, 51:495-500.
• [26]Agudelo CI, Sanabria OM, Ovalle MV: Serogroup Y Meningococcal Disease, Colombia. Emerg Infect Dis 2008, 14:990-991.
• [27]Nicolas P, Djibo S, Sidikou F, Tenebray B, Stor R, Boisier P, Chanteau S: Epidémies de Méningite à méningocoques du groupe X en Afrique en 2006. Med Trop 2006, 66:494.